Document registry — page 24
Every document the Institute has published, 1,639 in total, with its identifier, type, certainty rating and review date.
Documents
-
Phase 1 ascending dose, phase 1 study of Amycretin in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low20 Mar 2025 -
Phase 1 ascending dose, phase 1 study of Sermorelin in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low20 Mar 2025 -
Phase 1 ascending dose, phase 1 study of Cagrilintide in obesity over up to 20 weeks. The Institute holds no reported primary result for this record and publishes no…
Very low19 Mar 2025 -
Record of documents ratified in the 2025 Q1 assessment cycle.
18 Mar 2025 -
Residual solvent determination by static headspace gas chromatography
High18 Mar 2025 -
What proportion of the mass lost during treatment with an incretin receptor agonist is lean rather than fat mass, and does it differ from that lost through caloric…
Low17 Mar 2025 -
Consultation on the draft monograph for Dulaglutide, which the assessment committee released for public comment before ratification. The draft grades the compound's…
14 Mar 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Mazdutide in type 2 diabetes randomising 319 participants over 24 weeks. Primary result: A reduction of…
Moderate14 Mar 2025 -
Randomised, double-blind, placebo-controlled, phase 2 study of Maridebart cafraglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no…
Very low12 Mar 2025 -
Are the trials in the incretin evidence network sufficiently similar to support indirect comparison?
Moderate11 Mar 2025 -
Phase 1 ascending dose, phase 1 study of Mazdutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low11 Mar 2025 -
In the population defined for obesity and overweight in adults, what is the incidence of adverse events leading to discontinuation with Retatrutide compared with its…
Moderate10 Mar 2025 -
Randomised, double-blind, placebo-controlled, phase 1 study of Petrelintide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low06 Mar 2025 -
How is access to incretin-based obesity pharmacotherapy distributed, and what does the pattern of unregulated supply indicate about it?
Low05 Mar 2025 -
In the population defined for inflammatory bowel disease and mucosal barrier disorders, what is the effect of Larazotide acetate compared with the comparator used in its…
Moderate01 Mar 2025 -
Custom-synthesis peptides, SARMs, injectable oils and raw materials. 350+ catalogue lines with a custom-synthesis emphasis.
01 Mar 2025 -
Consultation on the draft monograph for GHK-Cu, which the assessment committee released for public comment before ratification. The draft grades the compound's principal…
27 Feb 2025 -
Fixed-ratio combination of a long-acting amylin analogue and a GLP-1 receptor agonist. The combination pairs two complementary satiation mechanisms: GLP-1 receptor agonism acting on hypothalamic and hindbrain appetite…
Moderate24 Feb 2025 -
Observational study of Epithalon in ageing over multi-year. Primary result: The Institute has not been able to obtain a protocol, a randomisation procedure or an…
24 Feb 2025 -
Established atherosclerotic disease of the coronary, cerebral or peripheral arterial beds, or a risk profile sufficient for enrolment in a cardiovascular outcome trial.
23 Feb 2025 -
Randomised crossover, phase 1 study of Amycretin in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low23 Feb 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Mazdutide in type 2 diabetes randomising 731 participants over 48 weeks. Primary result: A dose-dependent…
Moderate22 Feb 2025 -
Randomised, double-blind, placebo-controlled, phase 2 study of BPC-157 in mucosal barrier over as stated in the parent protocol. The Institute holds no reported primary…
Very low22 Feb 2025 -
Phase 1 ascending dose, phase 1 study of Selank in cognition over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low18 Feb 2025 -
Domain-specific cognitive function or protection against cognitive decline, assessed by standardised neuropsychological batteries or clinical dementia rating.
15 Feb 2025 -
Does treatment with a glucagon-like peptide-1 receptor agonist increase residual gastric content at the time of elective procedural sedation?
Low13 Feb 2025 -
In the population defined for type 2 diabetes mellitus, is the effect of Mazdutide maintained across the full duration of the contributing trials?
Moderate13 Feb 2025 -
Phase 1 ascending dose, phase 1 study of Survodutide in mash over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low13 Feb 2025 -
Event-driven kidney outcome trial, phase 3 study of Semaglutide in chronic kidney disease and type 2 diabetes randomising 3,533 participants over median 3.4 years…
High12 Feb 2025 -
Observational, phase 2 study of Survodutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low10 Feb 2025 -
Single-arm open-label, phase 3 study of Tirzepatide in hfpef and obesity over open-label extension of the parent trial. The Institute holds no reported primary result…
Very low08 Feb 2025 -
Long-acting amylin and calcitonin receptor agonist (acylated). Amylin is co-secreted with insulin and acts at the area postrema to promote meal-related satiation, and separately reduces gastric emptying and…
Moderate06 Feb 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in mash over as stated in the parent protocol. The Institute holds no reported primary result…
Very low05 Feb 2025 -
In the population defined for type 2 diabetes mellitus, what is the incidence of adverse events leading to discontinuation with Exenatide compared with its comparator?
High31 Jan 2025 -
Symptomatic heart failure with a left ventricular ejection fraction of 50 % or above, occurring with obesity as a dominant phenotypic driver.
29 Jan 2025 -
Single-arm open-label, phase 3 study of Tirzepatide in sleep apnoea and obesity over open-label extension of the parent trial. The Institute holds no reported primary…
Very low29 Jan 2025 -
Synthetic tetrapeptide. Epithalon is supplied on the premise that it activates telomerase and thereby extends replicative lifespan, on the basis of cell-culture reports of…
Very low26 Jan 2025 -
What in-use period can be supported for a reconstituted research peptide solution?
Moderate23 Jan 2025 -
Randomised crossover, phase 1 study of Tirzepatide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low22 Jan 2025 -
In the population defined for obesity and overweight in adults, what is the incidence of adverse events leading to discontinuation with Maridebart cafraglutide compared…
Low21 Jan 2025
page 24 of 41